Fanhdi®, efficacy and safety in von Willebrand's disease: Prospective international study results

Haemophilia

Volumn 13, Issue SUPPL. 5, 2007, Pages 25-32

  Bello, I F ^a   Yuste, V J ^a   Molina, M Q ^a   Navarro, F H ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Efficacy; Fanhdi ; Pharmacokinetic; Safety; Surgery; Von Willebrand

Indexed keywords

ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; DESMOPRESSIN; DEXCHLORPHENIRAMINE MALEATE; FANHDI; TRANEXAMIC ACID; UNCLASSIFIED DRUG; ARGIPRESSIN[1 DEAMINO]; COAGULATING AGENT; VON WILLEBRAND FACTOR;

ARTICLE; BLEEDING; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HEMOPHILIA A; HEMOSTASIS; HUMAN; MUCOSAL BLEEDING; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; SINGLE DRUG DOSE; VON WILLEBRAND DISEASE; ACUTE DISEASE; HALF LIFE TIME; MULTICENTER STUDY;

ACUTE DISEASE; COAGULANTS; DEAMINO ARGININE VASOPRESSIN; FACTOR VIII; HALF-LIFE; HEMORRHAGE; HEMOSTASIS, SURGICAL; HUMANS; PROSPECTIVE STUDIES; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 37149028751     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2007.01570.x     Document Type: Article

References (13)

1. Federici AB, Mannucci PM. Diagnosis and management of von Willebrand disease. Haemophilia 1999; 5: 28-37.
2. Sadler JE. Biochemistry and genetics of von Willebrand factor. Ann Rev Biochem 1998; 67: 395-424.
3. UK von Willebrand Working Party. Definition, inheritance, clinical features and diagnosis of Von Willebrand disease. Haemophilia 1997; 3: 1-8.
4. Mannucci PM. Treatment of Von Willebrand's disease. J Intern Med 1997; 242: 129-32.
5. Ewestein BM. Von Willebrand's disease. Ann Rev Med 1997; 48: 525-42.
6. Ong YL, Hull DR, Mayne EE. Menorrhagia in von Willebrand disease successfully treated with single daily dose tranexamic acid. Haemophilia 1998; 4: 63-5.
7. Hanley JA, Lippman-Hand A. If nothing is wrong, is everything all right? Interpreting zero numerators. JAMA 1983; 249: 1743-5.
8. Canales MA, Villar A, Magallón M et.al. Concentrado de FVIII de alta pureza con doble inactivación viral: Estudio de farmacocinética en pacientes con enfermedad de Von Willebrand [High, purity human factor VIII concentrate with two viral inactivation steps: Pharmacokinetic study in patients with Von Willebrand disease]. Sangre 1998; 43: 93-102.
9. Dobrkovska A, Krzensk U, Chediak JR. Pharmacokinetic, efficacy and safety of Humate-P ® in Von Willebrand disease. Haemophilia 1998; 4: 33-9.
10. Villar A, Jiménez-Yuste V, Canales M et.al. Use of a plasma-derived high-purity and double viral inactivated factor VIII concentrate in the treatment of von Willebrand disease. Thromb Haemost 1999; 82: 796.
11. Cox J. et.al. Successful treatment of urgent bleeding in Von Willebrand disease with factor VIII/VWF concentrate (Humate-P®): Use of the ristocetin cofactor assay (VWF:RCof) to measure potency and to guide therapy. Haemophilia 2003; 9: 688-95.
12. Foster P. A perspective on the use FVIII concentrates and cryoprecipitate prophylactically in surgery or therapeutically in severe bleeds in patients with von Willebrand disease unresponsive to DDAVP: results of an international survey. Thromb Haemost 1995; 74: 1370-8.
13. Lethagen S. Haemostatic treatment in connection with surgery in patients with Von Willebrand disease. Haemophilia 1995; 5: 64-7.